Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.542    0.002 (0.37%)
Bid:
0.542
Ask:
0.648
Spread: 0.106 (19.557%)
Market Cap: £3.15m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Total Voting Rights

1 Feb 2019 07:00

RNS Number : 7519O
Futura Medical PLC
01 February 2019
 

 

 

Futura Medical plc

("Futura" or "the Company")

Total Voting Rights

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 204,660,267 Ordinary Shares.

Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 204,660,267 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information please contact:

For media enquiries please contact:

 

 

Futura Medical plc

Optimum Strategic Communications

Angela Hildreth, FD/COO

Mary Clark/ Hollie Vile/ Ellie Blackwell

investor.relations@futuramedical.com

Email: futuramedical@optimumcomms.com

www.futuramedical.com

Tel: +44 (0) 203 950 9144

Tel: +44 (0) 1483 685 670

 

 

 

Nominated Advisor/Broker

 

N+1 Singer

 

Aubrey Powell/ Ben Farrow (Corporate Finance)

 

Tom Salvesen/ Mia Gardner (Corporate Broking)

 

Tel: +44 (0) 20 7496 3000

 

 

Notes to Editors

 

Futura Medical plc

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRZMGFMNMVGLZM
Date   Source Headline
6th Feb 200611:34 amRNSAdditional Listing
1st Feb 20067:00 amRNSAdditional Listing
3rd Jan 200612:50 pmRNSHolding(s) in Company
21st Dec 20054:14 pmRNSAdditional Listing
9th Dec 20057:01 amRNSRe: Global Rights
30th Nov 200510:18 amRNSAdditional Listing
28th Nov 20057:01 amRNSEU Marketing Submission
21st Nov 20057:02 amRNSStudy Results
7th Nov 20057:00 amRNSStudy Results
5th Sep 20057:00 amRNSInterim Results
12th Aug 20057:00 amRNSProduct development update
19th Jul 200511:00 amRNSNotice of Results
6th Jul 20057:00 amRNSSSL acquires rights to FLD500
5th Jul 200510:45 amRNSHolding(s) in Company
6th Jun 20053:38 pmRNSNotice of AGM
17th May 20052:44 pmRNSHolding(s) in Company
25th Apr 20057:00 amRNSManufacturing trials
22nd Mar 200510:11 amRNSGrant of options
21st Mar 20057:01 amRNSFinal Results
18th Mar 200512:58 pmRNSNotice of Results
28th Feb 20051:06 pmRNSChange of Advisers
1st Feb 20054:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.